Cervical Ganglioneuroblastoma Diagnosed by ⁶⁸Ga-DOTATOC PET/CT in a Child with Opsoclonus Myoclonus Syndrome

Kusai Al-Muqbel¹, Hamza Alardah¹, Ruba Al-Smadi¹, Sohaib Al-Khatib², and Raya Abughanmi³

¹Department of Radiology and Nuclear Medicine, Jordan University of Science and Technology, Irbid, Jordan; ²Department of Pathology, Jordan University of Science and Technology, Irbid, Jordan; and ³Department of Neurosurgery, Jordan University of Science and Technology, Irbid, Jordan

We performed a ⁶⁸Ga-DOTATOC PET/CT scan on a 25-mo-old female patient who presented with opsoclonus myoclonus ataxia syndrome and had negative initial anatomic imaging. The scan showed a somatostatin receptor-overexpressing cervical tumor in favor of a cervical neuroendocrine tumor, with subsequent histopathologic findings of ganglioneuroblastoma.

Key Words: ganglioneuroblastoma; ⁶⁸Ga-DOTATOC PET/CT; opsoclonus myoclonus syndrome

J Nucl Med Technol 2023; 00:1–2 DOI: 10.2967/jnmt.123.265776

N euroblastic tumors have been found to develop anywhere along the sympathetic nervous chain and are divided into 3 histologic categories—ganglioneuroma, ganglioneuroblastoma, and neuroblastoma—ranging from mature to immature tumors (1). The median age at diagnosis is 17 mo (2,3). Ganglioneuroblastomas account for 20% of neuroblastic tumors (4). Ganglioneuroblastomas arising from the neck are exceptionally rare (5).

Opsoclonus myoclonus ataxia syndrome (OMAS) is a rare neuroinflammatory disorder with multiple etiologies, and the neural-crest paraneoplastic eti-

ology is the most common (6).

It was found that ⁶⁸Ga-DOTApeptide PET/CT is the imaging modality of choice for well-differentiated neuroendocrine tumors because of its ability to locate the primary lesion and identify the extent of disease (7).

In the literature, we found a limited number of cervical ganglioneuroblastoma cases (only 16 cases) (5). We were unable to locate any case in which ⁶⁸Ga-DOTA-peptide PET/CT screening was used to diagnose cervical ganglioneuroblastoma. The objective of this case report is to demonstrate the value of ⁶⁸Ga-DOTA-TOC PET/CT in the diagnosis of cervical ganglioneuroblastoma while screening for clinically suspected neuroblastic tumors in a child who presented with OMAS. Institutional review board approval was waived for this case.

CASE REPORT

The pediatric unit referred a 25-mo-old girl with OMAS for a ⁶⁸Ga-DOTATOC PET/CT scan to screen for a potential neuroblastic tumor. The patient first underwent a contrast-enhanced torso CT scan, which was reported to be unremarkable.

A ⁶⁸Ga-DOTATOC PET/CT scan was performed afterward, revealing a tracer-avid soft-tissue mass in the right upper cervical region that was compatible with a somatostatin receptor-overexpressing tumor, in favor of a cervical neuroendocrine tumor. In addition, the scan revealed a tracer-avid enlarged right upper cervical lymph node suggestive of metastatic lymphadenopathy (Fig. 1). The scan was negative for tracer-avid distant metastases. A second look at the previously performed CT scan confirmed that there was a slightly enhanced soft-tissue mass in the right jugulodigastric region (Fig. 2). Neck MRI showed a well-defined heterogeneous



FIGURE 1. ⁶⁸Ga-DOTATOC PET/CT images (PET maximum-intensity projection, A; axial view, B; coronal view, C) showing tracer-avid right upper cervical mass.

soft-tissue mass measuring $1 \times 2.1 \times 2.7$ cm that had high T2 and low T1 signal intensities and was enhanced on the postcontrast T1 sequence. The mass extended from the skull base to the level of the C2 vertebra, with an extension into the right

Received Apr. 5, 2023; revision accepted Jul. 6, 2023.

For correspondence or reprints, contact Hamza Alardah (hamzaalarda@ yahoo.com).

Published online Aug. 16, 2023.

COPYRIGHT © 2023 by the Society of Nuclear Medicine and Molecular Imaging.



FIGURE 2. Contrast-enhanced CT images (coronal view, A; axial view, B) showing slightly enhanced soft-tissue mass in jugulodigastric region (arrow).

retropharyngeal space and partial encasement of the right internal carotid artery (Fig. 3). Also, the neck MRI revealed pathologic upper cervical lymph nodes.

Partial surgical resection was performed. Histopathology showed a nodular subtype of ganglioneuroblastoma (Fig. 4).

DISCUSSION

Our patient presented with OMAS, which is an immunemediated condition that may be paraneoplastic in the context of neuroblastoma. Peripheral neuroblastic tumors are found in 50% of children with OMAS. The most common tumor type is neuroblastoma (73%), followed by ganglioneuroblastoma (22%) and ganglioneuroma (4%) (8). Approximately 5% of peripheral neuroblastic tumors occur in the cervical region (5).

To our knowledge, this is the first case of cervical ganglioneuroblastoma that presented as paraneoplastic OMAS and was diagnosed by a ⁶⁸Ga-DOTATOC PET/CT scan.

Our case demonstrates the great value of ⁶⁸Ga-DOTApeptide PET/CT scanning in screening for clinically



FIGURE 3. Neck MRI showing right upper cervical mass (arrows) that is low signal on T1 sequence (coronal view, A), high signal on T2 sequence (coronal view, B), and enhanced on post-contrast T1 sequence (axial views, C and D).



FIGURE 4. (A and B) Histopathology showing nodules composed of stroma-poor islands of primitive cells with fibrillary neuropil matrix. (C) Synaptophysin staining in tumor cells. (D) Reticulin stain highlights nested pattern.

suspected neuroblastic tumors in children, as these tumors commonly overexpress somatostatin receptors (7). Tracers currently in clinical use are ⁶⁸Ga-DOTATOC, ⁶⁸Ga-DOTA-TATE, and ⁶⁸Ga-DOTANOC with high sensitivity (93%–96%) and high specificity (85%–100%) (9).

Our case is added to the 16 cases of cervical ganglioneuroblastoma reported in the literature. None of these 16 was diagnosed by ⁶⁸Ga-DOTA-peptide PET/CT scanning.

CONCLUSION

We reported a rare case of cervical ganglioneuroblastoma manifested clinically as OMAS and diagnosed by a ⁶⁸Ga-DOTATOC PET/CT scan of a 25-mo-old child.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

REFERENCES

- Jackson JR, Tran HC, Stein JE, et al. The clinical management and outcomes of cervical neuroblastic tumors. J Surg Res. 2016;204:109–113.
- Taran K, Owecka A, Kobos J. Prognostic importance of cyclin E1 expression in neuroblastic tumors in children. *Pol J Pathol.* 2013;64:149–152.
- Godkhindi VM, Basade MM, Khan K, Thorat K. Adult neuroblastoma: case report and literature review. J Clin Diagn Res. 2016;10:ED01–ED02.
- Ma R, Wang Y, He W. Primary orbital ganglioneuroblastoma: a case report. Open Med (Wars). 2021;16:1076–1081.
- Zeng Z, Liu J, Xu S, Qin G. Ganglioneuroblastoma in the retropharyngeal space: a case report and literature review. *Ear Nose Throat J.* 2022;9:1455613221101941.
- Yıldırım M, Öncel İ, Bektaş Ö, et al. Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome. *Eur J Paediatr Neurol*. 2022;41:19–26.
- Ambrosini V, Zanoni L, Filice A, et al. Radiolabeled somatostatin analogues for diagnosis and treatment of neuroendocrine tumors. *Cancers (Basel)*. 2022;14:1055.
- Rossor T, Yeh EA, Khakoo Y, et al. Diagnosis and management of opsoclonusmyoclonus-ataxia syndrome in children: an international perspective. *Neurol Neuroimmunol Neuroinflamm.* 2022;9:e1153.
- Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands: the next generation for clinical practice. *Am J Nucl Med Mol Imaging*. 2018;8:311–331.